HYPMY.US Hypera SA

Healthcare Pharmaceuticals USA Stocks
3.94 USD
Close of Nov 15, 2026
3.39 5.45
Market cap
USD 2.77B
P/E
7.6x
P/B
1.05x
ROE
12.2%
Dividend yield
5.14%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is HYPMY.US undervalued?

Graham number
Price3.94
Graham value6.63
Discount40.6%

HYPMY.US trades 40.6% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Hypera SA fundamental analysis

No fundamental analysis for Hypera SA yet.

Hypera SA stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Hypera SA

Hypera S.A. operates as a pharmaceutical company in Brazil. The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands; analgesics and anti-inflammatories products under the Doril, Atroveran, Calminex, Alivium, Buscopan, Buscofem, geloll, Torsilax, Neosaldina, and naprohax brands; cold and flu remedies and decongestants products under BENEGRIO, Rinosoro, Blu, Neosoro, Coristina, APRACUR, and Fluviral brands. It offers antihistamines products under A…

Full company profile